Prostate Cancer


This study will assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.

Trial overview


Prostate cancer


Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer.

Eligibility criteria

  • Metastatic Hormone Sensitive Prostate Cancer
  • Within 12 weeks of starting ADT

Study details

There is a screening period of 4 weeks to assess suitability for the trial. This is a randomised study with a ratio of 2:1 received the study therapy.  While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.


Further information

For more information regarding this clinical trial click here.


Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.